#monkey

Researchers have devised a means of injecting an antiretroviral under the skin that hardens into a dissolvable and removable implant.

An antibody treatment plus an immune-stimulating agent delayed viral rebound in primates infected with HIV-like virus.

Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.

The “kick-and-kill” strategy—waking up latently infected immune cells so as to kill them—did not reduce participants’ viral DNA.

This disappointment highlights the challenge of translating animal research into human trials.

Published results have updated preliminary findings presented at a previous conference.

NIH researchers have prompted animals to develop broadly neutralizing antibodies against the virus; an early human trial is in the works.

Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.

Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.

Scientists succeeded in editing the animals’ stem cells to resist an HIV-like virus and ultimately shrink their viral reservoir.

This sets the stage for an early human trial of such antibody injections for use as pre-exposure prophylaxis (PrEP) against HIV.

Merck’s investigational antiretroviral could one day be dosed only weekly among humans.

Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.

Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.

Researchers added more power to the vaccine that showed modest protection against humans in Thailand in 2009.

An HIV cure drug from Gilead Sciences, GS-9620, has shown promise in rhesus macaque monkeys.